Investment analysts at StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the stock.
Moleculin Biotech Price Performance
MBRX opened at $2.44 on Friday. The company’s 50 day simple moving average is $2.46 and its two-hundred day simple moving average is $3.74. Moleculin Biotech has a 1-year low of $2.12 and a 1-year high of $15.75.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($2.10) by ($0.13). Equities research analysts anticipate that Moleculin Biotech will post -8.6 EPS for the current year.
Institutional Trading of Moleculin Biotech
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Further Reading
- Five stocks we like better than Moleculin Biotech
- What is a Death Cross in Stocks?
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- Where Do I Find 52-Week Highs and Lows?
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Investing in the High PE Growth Stocks
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.